about
Cognitive performance in relapsing remitting multiple sclerosis: a longitudinal study in daily practice using a brief computerized cognitive battery.The cognitive and psychomotor effects of remacemide and carbamazepine in newly diagnosed epilepsy.Psychometric evaluation of the Work Readiness Questionnaire in schizophrenia.Cognition assessment in paediatric clinical trials.Approaches to measuring the effects of wake-promoting drugs: a focus on cognitive function.The role of human cognitive neuroscience in drug discovery for the dementias.Defining therapeutic benefit for people with schizophrenia: focus on negative symptoms.The effect of desvenlafaxine on cognitive functioning in employed outpatients with major depressive disorder: a substudy of a randomized, double-blind, placebo-controlled trial.Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms.Nabilone produces marked impairments to cognitive function and changes in subjective state in healthy volunteers.Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg.Cognitive performance by humans during a smoked cocaine binge-abstinence cycle.Cocaine users differ from normals on cognitive tasks which show poorer performance during drug abstinence.Effects of nicotine withdrawal on cognition in a clinical trial setting.Dapoxetine has no pharmacokinetic or cognitive interactions with ethanol in healthy male volunteersUse of Qualitative Data to Support Content Validity of Performance-Based Cognitive Outcome Assessments
P50
Q30474902-B220E6DA-33E5-4108-B01B-51CA3A8E7C87Q34911442-24A89A31-1A1C-4DE5-90A1-B84A2D602DE9Q36779063-6B36585F-082D-4B5D-8C73-18EEF865AB16Q37055407-F985E53E-3C90-4EF4-8C85-44EB6A6AFE16Q37355700-49E5B1FD-8686-47D9-9DEB-AA6FB922D268Q38190652-9076D00E-18D0-4976-908E-BED8347D1A8DQ38314448-6466A723-A1E0-4175-B3D9-E949DC5593CCQ38394430-061224D3-DFF9-4420-84F1-D27DBEB61ECDQ38982214-7F2ECB21-7305-40ED-BDEF-EAAA63BB46BDQ39971148-60B193DC-FB93-4F8E-8B23-871C428B322BQ43277955-6925BFF3-0F54-4BB3-BD99-7D894B9F378DQ46829636-42985D06-6516-41AC-9DBA-1C8756FA90A1Q46831396-65903499-D760-415D-9F9C-652274CE49F5Q50904740-71C0FBC5-DC0A-40ED-A9DD-6D17A0659DC4Q79830141-1334BA2A-4025-4DAF-B46F-563411F8F1A6Q91508519-1F6713F8-F6B9-432E-9654-C2876BA422FD
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Christopher Edgar
@en
Christopher Edgar
@nl
type
label
Christopher Edgar
@en
Christopher Edgar
@nl
prefLabel
Christopher Edgar
@en
Christopher Edgar
@nl
P31
P496
0000-0002-5638-9188